β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1459-1466

  Patlolla, Jagan M R ^a   Raju, Jayadev ^a,b   Swamy, Malisetty V ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; AZOXYMETHANE; BETA ESCIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FLOW CYTOMETRY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTESTINE CRYPT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; STRUCTURE ANALYSIS; WILD TYPE;

AESCULUS; ANIMALS; APOPTOSIS; AZOXYMETHANE; CARCINOGENS; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCIN; HCT116 CELLS; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; MALE; PLANT EXTRACTS; RATS; RATS, INBRED F344;

EID: 33746047529     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0495     Document Type: Article

References (50)

1. Ahmedin J, Taylor M, Alicia S, Asma G, Elizabeth W, Micheal JT. Cancer Statistics. CA- Cancer J Clinicians 2005;53:5-26.
2. Glovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31:925-43.
3. Milner JA, McDonald SS, Anderson DE, Greenwald P. Molecular targets for nutrients involved with cancer prevention. Nutr. Cancer 2001; 41:1-16.
4. Conney AH. Tailoring cancer chemoprevention regimens to the individual. J Cell Biochem 2004;91:277-86.
5. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
6. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem Suppl 1992;16G:55-62.
7. Cheng L, Lai MD. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol 2003;9:2642-9.
8. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002;43:1-21.
9. Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996;347:292-4.
10. Bielanski TE, Piotrowski ZH. Horse-chestnut seed extract for chronic venous insufficiency. J Fam Pract 1999;48:171-2.
11. Sirtori CR. Aescin: pharmacology, Pharmacokinetics and therapeutic profile. Pharmacol Res 2001;44:183-93.
12. Muraki K, Imaizumi Y, Watanabe M. Ca-dependent K channels in smooth muscle cells permeabilized by β-escin recorded using the cell-attached patch-clamp technique. Pflugers Arch 1992;420:461-9.
13. Pearson PJ, Vanhoutte PM. Vasodilator and vasoconstrictor substances produced by the endothelium. Rev Physiol Biochem Pharmacol 1993;122:1-67.
14. Berti F, Omini C, Longiave D. The mode of action of aescin and the release of prostaglandins. Prostaglandins 1977;14:241-9.
15. Matsuda H, Li Y, Yoshikawa M. Possible involvement of 5-HT and 5-HT2 receptors in acceleration of gastrointestinal transit by escin lb in mice. Life Sci 2000;66:2233-8.
16. Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch Pharm (Weinheim) 1990;328:20-4.
17. Tutton PJM, Barkla DH. Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth. Br J Cancer 1980;41: 47-51.
18. Stone OJ. Cancer resistance, carcinogenesis and ground substance viscosity. Med Hypotheses 1986;20:117-24.
19. Matsuda H, Li Y, Murakami T, Ninomiya K, Yamahara J, Yoshikawa M. Effects of escins la, lb, lla, and llb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull 1997;20:1092-5.
20. Marhuenda E, Alarcon de la Lastra C, Martin MJ. Antisecretory and gastroprotective effects of escine in rats. Gen Pharmacol 1994;25: 1213-9.
21. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000;100:71-8.
22. Bruce A, Edgar TL, Terry LO. Endoreplication cell cycles: more for less. Cell 2001;105:297-306.
23. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
24. Hunter T. Braking the cycle. Cell 1993;75:839-41.
25. Fischer PM, Lane DP. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr Med Chem 2000;7:1213-45.
26. American Institute of Nutrition. Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 1977;107:1340-8.
27. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-51.
28. Zbigniew D, Elzbieta B. Analysis of Apoptotic cells by flow and laser scanning cytometry. Methods Enzymol 2000;322:18-39.
29. Taya Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 1997;22:14-7.
30. Yang XW, Zhao J, Cui JR, Guo W. Studies on the biotransformation of escin la by human intestinal bacteria and the anti-tumor activities of desacylescin I. Beijing Da Xue Xue Bao 2004;36:31-5.
31. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993;14:2219-25.
32. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin a naturally occurring anti-inflammatory agent, during the promotion / progression stages of colon cancer. Cancer Res 1999;59: 597-601.
33. Rao CV, Desai D, Simi B, Kulkarni N, Amin S, Reddy BS. Inhibitory effect of caffeic acid esters on azoxymethane induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 1993;53:4182-8.
34. Rao CV, Desai D, Rivenson A, Simi B, Amin S, Reddy BS. Chemoprevention of colon carcinogenesis by phenylethyl-3-methyl caffeate. Cancer Res 1995;55:2310-5.
35. Raju J, Patiolla JM, Swamy MV, Rao CV. Diosgenin a steroid saponin of Trigonella foenum graecum (Fenugreek) inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomarkers Prev 2004;13:1392-8.
36. 1-phase progression. Genes Dev 1997;13:1501-12.
37. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92: 376-87.
38. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.
39. Senderowicz AM. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. In: Giaccone G, Schilsky RL, Sondel PM, editors. Cancer chemotherapy and biological response modifiers. Oxford (UK) Elsevier Science; 2001.
40. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
41. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
42. Mutoh M, Lung FD, Long YQ, Roller RP, Sikorski RS, O'Connor PMA. p21(Waf1/Cip1) carboxy-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 1999;59:3480-8.
43. WAF1/CIP1 complexes during the cell cycle. Proc Natl Acad Sci U S A 1998;95:12254-9.
44. Gartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999;246:280-9.
45. Violette S, Poulain L, Dussaulx E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002; 98:498-504.
46. Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002;59:126-42.
47. Chen PL, Scully P, Shew JY, Wang JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193-8.
48. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
49. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52.
50. WAF1/CIP1. Cancer Res 2005;65:3364-73.